NDAINJECTIONINJECTABLE
Approved
Dec 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
CELESTONE (betamethasone sodium phosphate) by Merck & Co. is clinical pharmacology glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. First approved in 1974.
Drug data last refreshed 17h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CELESTONE is a soluble injectable glucocorticoid (betamethasone sodium phosphate) developed by Merck & Co. and approved in 1974. It provides rapid anti-inflammatory and immunosuppressive activity across multiple organ systems through glucocorticoid receptor agonism. The sodium phosphate ester formulation enables prompt onset of action, making it suitable for acute inflammatory and immunological conditions requiring parenteral administration.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), the CELESTONE brand team is likely in defensive mode focused on retention and lifecycle extension rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease
Started Jan 2021
349 enrolled
Dry Eye Disease
Career Relevance
Worked on CELESTONE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.